CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia
CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia
复制标题
DOI：
10.1023/b:brea.0000019962.18922.87
复制
发表时间：
2004-04-01
影响因子：
3.8
通讯作者：
Zeillinger, R
中科院分区：
文献类型：
--
作者：
Schmid, BC;Rudas, M;Zeillinger, R
最近的证据归因于趋化因子及其受体对特定转移部位的癌细胞的运动、归巢和增殖的重要影响。在这里，我们报告CXCL 12（SDF-1 α）趋化因子受体CXCR 4在人导管原位癌（DCIS）和非典型导管增生中表达。CXCR 4在单纯DCIS和伴有浸润性病变的DCIS中均有表达。在66%的样本中，存在不典型导管增生，并且> 92%表现出CXCR 4染色阳性。CXCR 4在肿瘤发展的这一非常早期阶段的表达表明该受体在向这些细胞转移癌的过程中提供选择性优势中的作用。这些结果加强了靶向参与肿瘤进展和转移的趋化因子网络作为恶性疾病的治疗方法或作为化学预防策略的想法，阻断从癌前病变向恶性肿瘤的转变。
Recent evidence attributed important influence of chemokines and their receptors on motility, homing, and proliferation of cancer cells at specific metastatic sites. Here we report that the CXCL12 (SDF-1alpha) chemokine receptor CXCR4 is expressed in human ductal carcinoma in situ ( DCIS) as well as in atypical ductal hyperplasia. CXCR4 was expressed in pure DCIS and DCIS with concurrent invasive disease. In 66% of the samples, atypical ductal hyperplasia was present, and > 92% exhibited positive CXCR4-staining. Expression of CXCR4 at this very early step of tumor development indicates a role of this receptor in providing a selective advantage to such cells on their way to metastasizing carcinomas. These results strengthen the ideas to target chemokine networks involved in tumor progression and metastatis as a therapeutic approach in malignant disease or as a chemoprevention strategy, blocking the transition from premalignancy to malignancy.